Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug tirzepatide takes on alcohol addiction in new trial

NCT ID NCT06994338

Recruiting now Disease control Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a weekly injection of tirzepatide, a drug used for diabetes and weight loss, can help adults with alcohol use disorder and overweight or obesity reduce heavy drinking. About 42 participants will receive either the drug or a placebo for 8 weeks. The main goal is to see if the drug lowers the number of heavy drinking days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Behavior, Addictive Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL ALCOHOL USE DISORDER OBESITY AND OVERWEIGHT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Keck School of Medicine, University of Southern California

    RECRUITING

    Los Angeles, California, 90032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.